Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02GPG
|
|||
| Former ID |
DIB001966
|
|||
| Drug Name |
JNJ-42165279
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Phase 2 | [1] | |
| Social anxiety disorder [ICD-11: 6B04; ICD-10: F40.1] | Phase 2 | [2] | ||
| Company |
Janssen research & development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H17ClF2N4O3
|
|||
| Canonical SMILES |
C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl
|
|||
| InChI |
1S/C18H17ClF2N4O3/c19-13-3-4-22-10-14(13)23-17(26)25-7-5-24(6-8-25)11-12-1-2-15-16(9-12)28-18(20,21)27-15/h1-4,9-10H,5-8,11H2,(H,23,26)
|
|||
| InChIKey |
YWGYNGCRVZLMCS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1346528-50-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Inhibitor | [2] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02498392) An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.